We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider ...

Vibostolimab was part of a promising new category of immunotherapies known as anti-TIGIT. This type of drug binds to TIGIT ...

US pharma giant Merck & Co has announced the discontinuation of the clinical development programs for vibostolimab, an ...

Merck, known as MSD outside of the United States and Canada, announced the discontinuation of the clinical development programmes for vibostolimab, an anti-TIGIT antibody, and favezelimab, an anti-LAG ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the discontinuation of the clinical ...

Teos Therapeutics has potential lung cancer treatment despite issues and strong financial position. Read here to know why we ...

The drugmaker said that the agents vibostolimab and favezelimab failed to show benefit across numerous trials.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Merck said on Monday it has discontinued the development of two experimental cancer drugs after their failure in several ...

Both vibostolimab and favezelimab have had disappointing runs leading up to their termination, sustaining several late-stage ...

One LAG-3 drug has reached the market, namely Bristol-Myers Squibb's Opdualag, which combines its PD-1 inhibitor Opdivo ...

Merck discontinues TIGIT drug vibostolimab and LAG-3 drug favezelimab after Phase 3 failures with Keytruda in lung cancer and ...